Cargando…

DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells

Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies and is known to be associated with the accumulation of various genetic and epigenetic alterations. As a member of the human histone-lysine N-methyltransferase SETD1A (SET1)/histone-lysine N-methyltransferase 2A (MLL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lili, Zhang, Shuguang, Li, Aihua, Zhang, Anqi, Zhang, Shiqian, Chen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202113/
https://www.ncbi.nlm.nih.gov/pubmed/30221689
http://dx.doi.org/10.3892/ijmm.2018.3869
_version_ 1783365641207545856
author Zhang, Lili
Zhang, Shuguang
Li, Aihua
Zhang, Anqi
Zhang, Shiqian
Chen, Liang
author_facet Zhang, Lili
Zhang, Shuguang
Li, Aihua
Zhang, Anqi
Zhang, Shiqian
Chen, Liang
author_sort Zhang, Lili
collection PubMed
description Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies and is known to be associated with the accumulation of various genetic and epigenetic alterations. As a member of the human histone-lysine N-methyltransferase SETD1A (SET1)/histone-lysine N-methyltransferase 2A (MLL) complexes that are required for full SET1/MLL methyltransferase activity, protein dpy-30 homolog (DPY30) catalyzes histone H3K4 methylation, and its dysfunction has been associated with the occurrence of cancer. Therefore, the present study investigated the role of DPY30 in EOC and the potential association between DPY30 expression and the clinicopathological characteristics of EOC. The expression of DPY30 was examined in EOC tissues and cell lines to identify any correlations between the clinico-pathological characteristics of EOC and DPY30 expression, and to determine the effects of DPY30 on EOC cell proliferation, migration and invasion. DPY30 was highly expressed in EOC tissues and cell lines, and high DPY30 expression was significantly associated with notable clinicopathological variables in EOC patients, including International Federation of Gynecology and Obstetrics stage, pathological grade and lymph node metastasis. Functional studies on EOC cell lines demonstrated that DPY30 significantly promoted cell proliferation, migration, and invasion, accelerated cell cycle progression, and promoted epithelial-mesenchymal transition. Chromatin immunoprecipitation assay results revealed that DPY30 regulates histone H3K4 modification via interaction with the vimentin gene promoter, suggesting that DPY30 promotes the transcription of vimentin. Finally, high expression of DPY30 was significantly associated with reduced survival in patients with EOC. The results indicated that DPY30 may act as an oncogene in EOC and thus represents a potential therapeutic target and prognostic marker in EOC.
format Online
Article
Text
id pubmed-6202113
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-62021132018-11-07 DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells Zhang, Lili Zhang, Shuguang Li, Aihua Zhang, Anqi Zhang, Shiqian Chen, Liang Int J Mol Med Articles Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies and is known to be associated with the accumulation of various genetic and epigenetic alterations. As a member of the human histone-lysine N-methyltransferase SETD1A (SET1)/histone-lysine N-methyltransferase 2A (MLL) complexes that are required for full SET1/MLL methyltransferase activity, protein dpy-30 homolog (DPY30) catalyzes histone H3K4 methylation, and its dysfunction has been associated with the occurrence of cancer. Therefore, the present study investigated the role of DPY30 in EOC and the potential association between DPY30 expression and the clinicopathological characteristics of EOC. The expression of DPY30 was examined in EOC tissues and cell lines to identify any correlations between the clinico-pathological characteristics of EOC and DPY30 expression, and to determine the effects of DPY30 on EOC cell proliferation, migration and invasion. DPY30 was highly expressed in EOC tissues and cell lines, and high DPY30 expression was significantly associated with notable clinicopathological variables in EOC patients, including International Federation of Gynecology and Obstetrics stage, pathological grade and lymph node metastasis. Functional studies on EOC cell lines demonstrated that DPY30 significantly promoted cell proliferation, migration, and invasion, accelerated cell cycle progression, and promoted epithelial-mesenchymal transition. Chromatin immunoprecipitation assay results revealed that DPY30 regulates histone H3K4 modification via interaction with the vimentin gene promoter, suggesting that DPY30 promotes the transcription of vimentin. Finally, high expression of DPY30 was significantly associated with reduced survival in patients with EOC. The results indicated that DPY30 may act as an oncogene in EOC and thus represents a potential therapeutic target and prognostic marker in EOC. D.A. Spandidos 2018-12 2018-09-11 /pmc/articles/PMC6202113/ /pubmed/30221689 http://dx.doi.org/10.3892/ijmm.2018.3869 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhang, Lili
Zhang, Shuguang
Li, Aihua
Zhang, Anqi
Zhang, Shiqian
Chen, Liang
DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
title DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
title_full DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
title_fullStr DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
title_full_unstemmed DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
title_short DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
title_sort dpy30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202113/
https://www.ncbi.nlm.nih.gov/pubmed/30221689
http://dx.doi.org/10.3892/ijmm.2018.3869
work_keys_str_mv AT zhanglili dpy30isrequiredfortheenhancedproliferationmotilityandepithelialmesenchymaltransitionofepithelialovariancancercells
AT zhangshuguang dpy30isrequiredfortheenhancedproliferationmotilityandepithelialmesenchymaltransitionofepithelialovariancancercells
AT liaihua dpy30isrequiredfortheenhancedproliferationmotilityandepithelialmesenchymaltransitionofepithelialovariancancercells
AT zhanganqi dpy30isrequiredfortheenhancedproliferationmotilityandepithelialmesenchymaltransitionofepithelialovariancancercells
AT zhangshiqian dpy30isrequiredfortheenhancedproliferationmotilityandepithelialmesenchymaltransitionofepithelialovariancancercells
AT chenliang dpy30isrequiredfortheenhancedproliferationmotilityandepithelialmesenchymaltransitionofepithelialovariancancercells